[go: up one dir, main page]

PL3810281T3 - Sposoby leczenia nowotworów dwuswoistymi przeciwciałami anty- cd3xmuc16 i przeciwciałami anty-pd-1 - Google Patents

Sposoby leczenia nowotworów dwuswoistymi przeciwciałami anty- cd3xmuc16 i przeciwciałami anty-pd-1

Info

Publication number
PL3810281T3
PL3810281T3 PL19739472.9T PL19739472T PL3810281T3 PL 3810281 T3 PL3810281 T3 PL 3810281T3 PL 19739472 T PL19739472 T PL 19739472T PL 3810281 T3 PL3810281 T3 PL 3810281T3
Authority
PL
Poland
Prior art keywords
antibodies
cd3xmuc16
methods
treating cancer
bispecific
Prior art date
Application number
PL19739472.9T
Other languages
English (en)
Inventor
Alison CRAWFORD
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL3810281T3 publication Critical patent/PL3810281T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19739472.9T 2018-06-21 2019-06-20 Sposoby leczenia nowotworów dwuswoistymi przeciwciałami anty- cd3xmuc16 i przeciwciałami anty-pd-1 PL3810281T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862688251P 2018-06-21 2018-06-21
PCT/US2019/038163 WO2019246356A1 (en) 2018-06-21 2019-06-20 Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
PL3810281T3 true PL3810281T3 (pl) 2024-11-04

Family

ID=67254001

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19739472.9T PL3810281T3 (pl) 2018-06-21 2019-06-20 Sposoby leczenia nowotworów dwuswoistymi przeciwciałami anty- cd3xmuc16 i przeciwciałami anty-pd-1

Country Status (25)

Country Link
US (1) US11254752B2 (pl)
EP (2) EP3810281B1 (pl)
JP (1) JP7403480B2 (pl)
KR (1) KR20210023981A (pl)
CN (1) CN112312970A (pl)
AU (1) AU2019290170A1 (pl)
BR (1) BR112020025476A2 (pl)
CA (1) CA3103887A1 (pl)
CL (1) CL2020003256A1 (pl)
DK (1) DK3810281T3 (pl)
EA (1) EA202190088A1 (pl)
ES (1) ES2984972T3 (pl)
FI (1) FI3810281T3 (pl)
HU (1) HUE067985T2 (pl)
IL (1) IL279251A (pl)
MA (1) MA52962B1 (pl)
MX (1) MX2020013905A (pl)
PH (1) PH12020552115A1 (pl)
PL (1) PL3810281T3 (pl)
PT (1) PT3810281T (pl)
RS (1) RS65886B1 (pl)
SG (1) SG11202012137UA (pl)
TW (1) TW202005985A (pl)
WO (1) WO2019246356A1 (pl)
ZA (1) ZA202007599B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
MA53495A (fr) 2018-08-31 2021-12-08 Regeneron Pharma Stratégie de dosage permettant d'atténuer le syndrome de libération de cytokines pour des anticorps bispécifiques cd3/c20
US20220233690A1 (en) 2021-01-28 2022-07-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
WO2022197907A2 (en) * 2021-03-18 2022-09-22 Memorial Sloan-Kettering Cancer Center Methods for treating gynecologic cancer using combination therapy with anti-muc16 x cd3 multispecific antibodies and vegf inhibitors
TW202325343A (zh) 2021-08-31 2023-07-01 日商日本醫事物理股份有限公司 去醣基化抗體之放射性複合體，及放射性醫藥
IL312813A (en) * 2021-11-24 2024-07-01 Regeneron Pharma Methods for treating cancer using bispecific antibodies against CD3 and MUC16 and antibodies against CTLA-4
EP4460520A1 (en) * 2022-01-07 2024-11-13 Regeneron Pharmaceuticals, Inc. Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
JP2025504795A (ja) 2022-01-10 2025-02-19 ナンチン リーズ バイオラブス カンパニー，リミティド 抗体及びその用途
WO2023176881A1 (ja) * 2022-03-16 2023-09-21 第一三共株式会社 多重特異的分子と免疫チェックポイント阻害剤の組み合わせ
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
US20240277844A1 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
HU228477B1 (en) 1999-08-23 2013-03-28 Dana Farber Cancer Inst Inc Pd-1, a receptor for b7-4, and uses therefor
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
WO2010151792A1 (en) 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
KR20140041598A (ko) 2011-07-24 2014-04-04 큐어 테크 리미티드 인간화된 면역조절 모노클로날 항체의 변이체
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2901133T3 (es) * 2015-09-23 2022-03-21 Regeneron Pharma Anticuerpos biespecíficos anti-CD3 optimizados y usos de los mismos
WO2017112775A1 (en) * 2015-12-22 2017-06-29 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
TWI786044B (zh) * 2016-05-13 2022-12-11 美商再生元醫藥公司 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
ES2952735T3 (es) 2016-09-23 2023-11-03 Regeneron Pharma Anticuerpos anti-MUC16-CD3 biespecíficos y conjugados anti-MUC16-fármaco
CA3039930A1 (en) * 2016-10-14 2018-04-19 Xencor, Inc. Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof

Also Published As

Publication number Publication date
EP4424712A3 (en) 2024-11-13
RS65886B1 (sr) 2024-09-30
PH12020552115A1 (en) 2021-08-02
MA52962B1 (fr) 2024-10-31
CN112312970A (zh) 2021-02-02
US11254752B2 (en) 2022-02-22
CL2020003256A1 (es) 2021-04-30
FI3810281T3 (fi) 2024-08-14
DK3810281T3 (da) 2024-08-19
JP2021528423A (ja) 2021-10-21
EP4424712A2 (en) 2024-09-04
EP3810281B1 (en) 2024-07-24
HUE067985T2 (hu) 2024-12-28
MA52962A (fr) 2021-04-28
PT3810281T (pt) 2024-08-02
EP3810281A1 (en) 2021-04-28
SG11202012137UA (en) 2021-01-28
BR112020025476A2 (pt) 2021-03-16
TW202005985A (zh) 2020-02-01
WO2019246356A1 (en) 2019-12-26
MX2020013905A (es) 2021-03-09
US20190389966A1 (en) 2019-12-26
CA3103887A1 (en) 2019-12-26
AU2019290170A1 (en) 2021-01-07
ES2984972T3 (es) 2024-10-31
EA202190088A1 (ru) 2021-03-22
IL279251A (en) 2021-01-31
ZA202007599B (en) 2025-02-26
KR20210023981A (ko) 2021-03-04
JP7403480B2 (ja) 2023-12-22

Similar Documents

Publication Publication Date Title
IL279251A (en) Methods for treating cancer with bispecific antibodies against CD3XMUC16 and antibodies against PD-1
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
IL276303A (en) Methods of treating cancer with ANTI-PD-1 antibodies
IL289946A (en) Bispecific antibodies against cd3 and cd20
IL283530A (en) Bispecific anti-pd-l1/anti-4-1bb antibodies and their uses
IL275096A (en) Antibodies against PD-1 and treatment methods
LT3394103T (lt) Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
ZA202005223B (en) Methods of treating cancers with antagonistic anti-pd-1 antibodies
IL248511A0 (en) Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
SG11201705252UA (en) Anti-pd-1 monoclonal antibodies and obtaining method thereof
IL266990A (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
IL275940A (en) Combined treatment with antibodies against IL-8 and against PD-1 for cancer treatment
SG10201912545PA (en) T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
IL281441A (en) Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer
IL286504A (en) Anti-cd73, anti-pd-l1 antibodies and chemotherapy for tumor treatment
IL272669A (en) Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer
ZA202204422B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
SG11202103589XA (en) Materials and methods for treating cancer
IL287687A (en) Methods of treating cancer with an anti-pd-l1 antibody
ZA202204423B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
ZA202204252B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
GB201819026D0 (en) Means and methods for treating cancer